Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib and Lenalidomide in Smoldering and Active Multiple Myeloma
NCT03815279Phase 2Enrolling by invitation
- Sponsor
- Landspitali
- Start
- Jun 2019
- Primary completion
- Jan 2024
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of carfilzomib in multiple myeloma (MM) and smoldering multiple myeloma (SMM) (2 arms), sponsored by Landspitali. Primary endpoint: Rate of Minimal Residual Disease (MRD) negativity at 36 months. Started Jun 2019; status: enrolling by invitation.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT03815279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03815279.